🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#TMUS, #COCO, #ITCI, #LKQ, #AISP

#OptionFlow #OptionsTrading #Trading

Halper Sadeh LLC Launches Investigations into ITCI, PWOD, and EBTC Shareholder Rights Halper Sadeh LLC is probing multiple companies, including ITCI and PWOD, over potential violations of securities laws. Shareholders may have rights worth exploring.

Halper Sadeh LLC Launches Investigations into ITCI, PWOD, and EBTC Shareholder Rights #United_States #New_York #EBTC #PWOD #ITCI

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results Intra-Cellular Therapies (ITCI) reported strong financial results for Q4 and full-year 2024. CAPLYTA net product sales reached $199.2 million in Q4 2024, showing 51% growth compared to Q4 2023. Full-year 2024 CAPLYTA sales were $680.5 million, up 47% year-over-year.The FDA accepted the supplemental New Drug Application (sNDA) for lumateperone as adjunctive treatment for major depressive disorder (MDD). The company expanded its field sales force in anticipation of potential MDD approval. R&D expenses increased to $236.1 million in 2024 from $180.1 million in 2023, while SG&A expenses rose to $504.5 million from $409.9 million.The company's cash position strengthened to $1.0 billion by end of 2024, up from $499.7 million in 2023. ITCI initiated 10 late-stage clinical trials in 2024, including six Phase 3 lumateperone trials and four ITI-1284 trials.

#ITCI Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

www.stocktitan.net/news/ITCI/intra-cellular...

Johnson & Johnson to Acquire CAPLYTA-Maker Intra-Cellular in $14.6B Mental Health Push J&J expands neuroscience portfolio with acquisition of Intra-Cellular Therapies, gaining CAPLYTA®, a multi-indication mental health drug with $5B+ peak sales potential.

#ITCI Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

www.stocktitan.net/news/ITCI/johnson-johnso...

Johnson & Johnson Acquires Intra-Cellular for $14.6B, Adding Breakthrough Mental Health Drug CAPLYTA JNJ expands neuroscience portfolio with $132/share acquisition of Intra-Cellular, gaining CAPLYTA®, a multi-indication mental health treatment with $5B+ peak sales potential.

#JNJ #ITCI Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

www.stocktitan.net/news/JNJ/johnson-johnson...

J&J #JNJ Is in Talks to Buy $10 Billion Biotech Intra-Cellular #ITCI

Breaking News: ( NASDAQ: #ITCI ) Intra-Cellular Therapies Settles CAPLYTA (lumateperone) Patent Litigation with Sandoz

Intra-Cellular Therapies Secures CAPLYTA Patent Protection Until 2040 in Sandoz Settlement Intra-Cellular Therapies reaches landmark settlement with Sandoz, protecting CAPLYTA from generic competition until 2040. Key CNS disorder drug maintains market exclusivity.

#ITCI Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz 

www.stocktitan.net/news/ITCI/intra-cellular...

#ITCI Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

www.stocktitan.net/news/ITCI/intra-cellular...

JUST IN: ( NASDAQ: #ITCI ) Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

#StockMarket #News

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#JMIA, #HPE, #ITCI, #NVDL, #XPO

#OptionFlow #OptionsTrading #Trading